10:43 AM EDT, 06/03/2024 (MT Newswires) -- Precigen ( PGEN ) shares rose 19% in recent Monday trading after the company said data from a phase 1/2 study of its investigational PRGN-2012 AdenoVerse gene therapy showed 51% of patients with recurrent respiratory papillomatosis achieved complete response, requiring no surgeries following treatment.

The treatment lowered the need for surgeries in 86% of patients, compared with their pre-treatment history, and was well-tolerated, with no dose-limiting toxicities and no treatment-related adverse events greater than grade 2.

The company plans to share the results with the US Food and Drug Administration as part of a rolling biologics license application submission under an accelerated approval pathway, Precigen ( PGEN ) Chief Executive Officer Helen Sabzevari said in a statement.

Price: 1.67, Change: +0.27, Percent Change: +18.93